Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042373 (vascular disease)
 17,070 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Atherosclerotic plaque disruption is the predominant pathogenetic mechanism underlying the acute coronary syndromes. Plaque rupture leads to the exposure of collagen and vessel media, resulting in platelet and clotting activation, and occlusive thrombus formation. While drugs that interfere with platelet activation and function have been available for years, more powerful agents with novel mechanisms of action are being developed. Of the available platelet inhibitor drugs, only aspirin, sulfinpyrazone, and dipyridamole have undergone extensive clinical testing in patients with cardiovascular disease. More recently ticlopidine, a new and potent platelet inhibitor, has been successfully tested in patients with coronary and vascular disease. In acute myocardial infarction, aspirin significantly reduces cardiovascular mortality and reinfarction. Furthermore, the combination of aspirin and a thrombolytic agent produces maximal benefit. A role for heparin in the prevention of early mortality and reinfarction is emerging. This drug is effective for the prevention of left ventricular thrombosis in patients with anterior myocardial infarction. In the secondary prevention of reinfarction and cardiovascular mortality, available data support the use of a platelet inhibitor. Trials have shown that aspirin is as effective alone as in combination with dipyridamole, and is probably more effective than sulfinpyrazone. Long-term anticoagulant therapy also appears to be beneficial, but is associated with a high cost, need for extensive monitoring, and potential for hemorrhagic side effects. The role of aspirin in primary prevention is controversial. It may be indicated for patients at high risk for coronary disease in whom the benefit of therapy may outweigh the potential risk of cerebral bleeding. Coronary atherosclerotic plaque rupture, associated with thrombus formation, is fundamental to the development of acute myocardial infarction. Based on this concept, the role of antithrombotic therapy for the prevention or treatment of ischemic events in patients with coronary artery disease has stimulated enormous interest among clinicians and basic investigators. In this review we will examine: a) the pathogenesis of coronary thrombosis, b) the pharmacology of platelet-inhibitor agents, and c) their role in the management of patients with acute myocardial infarction and in primary and secondary prevention of cardiovascular disease. Platelets interact with both the coagulation and fibrinolytic systems in the pathogenesis of thrombosis.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Role of platelet inhibitor therapy in myocardial infarction. 248 43

Cardiovascular diseases represent a major cause of morbidity and mortality in both obese and diabetic patients. The mechanisms by which diabetes or obesity cause the cardiac lesions is poorly understood. A number of risk factors associated with the development of atherosclerotic vascular disease, a precursor of heart disease, are found in diabetes and obesity. There is evidence that diabetes or obesity may even cause a primary cardiomyopathy. The use of animal models with obesity or diabetes with various combinations of risk factors may clarify what each component contributes to the expression of cardiovascular disease. This report summarizes some of the current information on the cardiovascular complications found in various animal models of obesity and diabetes.
 ...
PMID:Cardiovascular disease in genotypes for obesity and diabetes. 252 Feb 59

In this review of cardiovascular effects of oral contraceptives (OCs), the risks are identified from 2 prospective cohort studies as 19/10,000 woman years for the risk of thrombosis or thromboembolism. 11 of 19 were superficial thrombosis and 8 were deep vein thrombosis or pulmonary embolism. For women with no risk factors, the risk was 2.0 for superficial thrombosis and 4.0 for deep vein thrombosis. Myocardial infarction (MI) risk is estimated at 7/100,000 current users/year for women 30-39 years and 67/100,000/year for women 40-44 years based on combined British and American studies. 37/100,000/year is the estimated risk for women 30-44 years for either thrombotic or hemorrhagic stroke. 50% of the MIs and 10% of the strokes were fatal. The total annual risk of death from any circulatory disease was estimated at 22-24 deaths/100,000 women years based on 2 British cohort studies. Other predisposing factors also contribute to cardiovascular disease, and separating out the effects has been controversial. In 1985, a study refuted that OCs were responsible for any effect on cardiovascular risk, because of flawed case control studies. One such study is cited which shows that only 16.7% of OC users were confirmed by Doppler ultrasound for deep vein thrombosis compared with 30.7% for nonusers. The general trend in the UK is one of reduced death rates from circulatory disease for women in spite of widespread contraceptive use. This relationship between OC use and cardiovascular disease was evidenced in another study of vital statistics from 21 countries. The pathological mechanisms for the association between OC use and vascular disease are discussed for blood clotting with the importance of predisposing factors highlighted, MI and lipid metabolism and other risk factors, stroke, and breakthrough bleeding. The risk is very low for vascular disease with available low- dose preparations. Risk is further reduced with careful screening of high risk women. The side effects of low-dose pills such as breakthrough bleeding can be treated with cautious use of alternative high-dose formulations and patient education. Low-dose OCs with 30-35 mg of estrogen combined with a low-dose and low androgenic progestin are recommended.
 ...
PMID:Cardiovascular effects of oral contraceptives: a review. 257 58

The prevention of cardiovascular disease antedates our current preoccupation with risk factors for coronary heart disease and hypertension. Indeed, earlier preventive efforts have in part been so successful that many people have forgotten that they existed. The almost forgotten entity, beriberi heart disease, was first prevented in 1883 by Takaki of Japan. With diphtheria, it was the identification of the causative bacillus by Klebs in 1883, leading finally to the development of diphtheria toxoid by Ramon in 1923, which resulted in the disappearance of diphtheritic heart disease. Success in the attack on syphilitic heart and vascular disease began with Bordet and Gengou in 1901 with the discovery of the phenomenon of complement fixation, and with the formulation of Salvarsan by Ehrlich in 1907. The story of the prevention of rheumatic fever has a large cast of characters, but special recognition must be given to Coburn for his observations confirming the role of the hemolytic streptococcus published in 1931 and showing the prophylactic value of sulfanilamide published in 1939. The important association of maternal rubella with congenital heart malformations was revealed by Gregg in 1941. Alcoholic heart disease was identified particularly by Brigden and Evans in 1957 and 1959, respectively. In relation to coronary and hypertensive heart disease, the names of Anitschkow (1933), Leary (1935), and Keys (1948) in relation to diet, of Freis (1967) in the field of hypertension treatment, of White (1927) in relation to physical exercise, and of English, Willius, and Berkson (1940) and Hammond and Horn (1954) in the role of cigarette smoking, deserve special recognition.
 ...
PMID:Background of the prevention of cardiovascular disease. II. Arteriosclerosis, hypertension, and selected risk factors. 266 Oct 54

A variety of industrial agents to which large segments of the population are exposed have been linked to the development of cardiovascular disease. These toxic agents, which include carbon monoxide, carbon disulphide, lead, and cadmium, are produced by a wide variety of industrial processes and so are ubiquitous in the modern industrial environment. Although the mechanisms by which such toxins may contribute to cardiovascular disease are not well defined, there are at least four possible theories that have received clinical and experimental support. The postulated mechanisms by which such toxins may play a role in vascular disease are: (1) an increase in blood pressure; (2) an increase in the levels of blood cholesterol and/or an induction of lipid accumulation in vessel walls; (3) an induction of a lipid peroxidation process thereby increasing the tendency of blood clotting; and (4) a promotion of a mutation in the arterial cell wall.
 ...
PMID:Carbon monoxide, carbon disulfide, lead and cadmium--four examples of occupational toxic agents linked to cardiovascular disease. 268 48

We studied the relationship between parental history of cardiovascular disease and risk for adverse lipid and lipoprotein levels in a total community study of 3313 children (ages 4 to 17 years, 63% white, 37% black). Older white children (11 to 17 years) with a parental history of heart attack or diabetes were 4.3 and 5.6 times, respectively, more likely to have high levels (greater than or equal to 95th percentile) of serum total cholesterol than those without such a history (all p less than 0.05). White children with a parental history of heart attack or diabetes were twice as likely to have an elevated (greater than or equal to 95th percentile) low-density lipoprotein cholesterol (LDL-C) level than those without such a history (both p less than 0.05). In contrast, parental history of cardiovascular disease did not predict elevated levels of total cholesterol or LDL-C in black children. However, older black children with a parental history of heart attack, hypertension, or diabetes were 4 1/2 to 5 times more likely to have low levels (less than or equal to 5th percentile) of high-density lipoprotein cholesterol than those without such a history (all p less than 0.05). Only 40% of white children and 21% of black children with elevated LDL-C levels had a parental history of vascular disease. These findings raise questions about the current practice of screening only children with a family history of cardiovascular disease to identify those with elevated total cholesterol and LDL-C levels.
 ...
PMID:Parental history of cardiovascular disease as an indication for screening for lipoprotein abnormalities in children. 275 48

A study was initiated to determine whether alveolar macrophages from patients with collagen vascular diseases but free of pulmonary symptoms were spontaneously activated and whether they released various mediators related to the pathogenesis of pulmonary fibrosis. Alveolar macrophages obtained by bronchoalveolar lavage from 32 patients with proved collagen vascular disease but no evidence of lung disease were compared with those from 10 patients with collagen vascular disease with interstitial lung disease (CVD-ILD) and from 10 healthy controls. The total number of alveolar macrophages did not differ between patients with collagen vascular disease and controls but were substantially increased in the CVD-ILD group. Alveolar macrophages from 31 of the 32 patients with collagen vascular disease and from all 10 in the CVD-ILD group had at least one criterion of activation. Neutrophil chemotactic activity was detected in supernatants from alveolar macrophage culture in 23 of the 32 patients with collagen vascular disease and from nine of the 10 in the CVD-ILD group; fibronectin secretion by alveolar macrophages was increased in 12 of the 32 patients with collagen vascular disease and in nine of the 10 in the CVD-ILD group. Furthermore, alveolar macrophages from 20 of the 32 patients with collagen vascular disease and four of the 10 CVD-ILD patients spontaneously released increased amounts of superoxide anion. Thus alveolar macrophages were spontaneously activated in a high proportion of patients with collagen vascular disease.
 ...
PMID:Activated alveolar macrophages in subclinical pulmonary inflammation in collagen vascular diseases. 283 61

Hypertension is a major risk factor for arteriosclerotic vascular disease. Despite intensive antihypertensive intervention, the risk of cardiovascular disease has not declined appreciably. Many of the antihypertensive agents have been shown to elevate total serum cholesterol and triglyceride levels or lower the high-density lipoprotein-cholesterol level. Thus, the antihypertensive agents chosen may negate the beneficial effects of a lower blood pressure. Our purpose is to review all available antihypertensive medications and their influence on lipoprotein metabolism. Choosing the antihypertensive therapy least likely to worsen or precipitate other known cardiovascular risk factors is important. Cost and side effect profiles must also be considered in choosing the best antihypertensive regimen for your patients.
 ...
PMID:The effects of antihypertensive agents on serum lipids and lipoproteins. 289 34

PARD is a prospective study sponsored by the German research council with the aim to establish whether spontaneously enhanced platelet aggregation or changes of other hemostatic parameters are risk factors for new vascular occlusion in diabetic patients. Hemostatic parameters have been measured in diabetic patients at 3 month-intervals (363 patients aged 45-65 at recruitment). Of the 232 men, 53 were on diet, 104 on oral antidiabetic drugs and 75 on insulin. Of 131 women 16 were on diet, 46 on oral antidiabetic drugs and 69 on insulin. Baseline data and preliminary results obtained between May 1977 and December 31, 1983 are presented. 22 patients have died. 17 diet from cardiovascular disease, 3 from pancreatic cancer and 2 from other causes. 51 patients suffered a myocardial infarction, stroke or peripheral arterial occlusions. The mean levels of spontaneous aggregation (angle alpha-PAT III), F VIIIC, F VIII R:AG, fibrinogen, antithrombin III and plasminogen were higher in men who died or suffered cardiovascular occlusions than in those without these events. In women this difference is less pronounced or absent. In women the mean values of several hemostatic parameters at baseline were higher than in men and the incidence of cardiovascular occlusions was lower. The interim results lead to the hypothesis that spontaneous aggregation, high levels of F VIIIC, F VIII R:AG and to some extent also high levels of fibrinogen, antithrombin III and plasminogen may be indicators of progressive vascular disease and could be useful as predictors of vascular occlusions.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:PARD: platelet aggregation as a risk factor in diabetics: results of a prospective study. 293 12

This report describes the nuclear cardiology procedures available for use as diagnostic techniques in patients with definite or suspected cardiovascular disease. The usefulness of myocardial imaging, radionuclide angiocardiography and other radionuclide cardiovascular imaging techniques is classified within specific disease states. The clinical utility of each technique is graded from I to IV, depending on the clinical importance of the technique (I = most important; IV = not indicated). A grade of V is given for methods now considered to be in their research phase. The usefulness of these methods is discussed in patients with acute ischemic heart disease, chronic ischemic heart disease, valvular heart disease, pulmonary vascular disease and hypertensive heart disease. Selected references are provided.
 ...
PMID:Guidelines for Clinical Use of Cardiac Radionuclide Imaging, December 1986. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on Nuclear Imaging). 294 47


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>